Industry Insights

  • Has the booming PD-1 inhibitor reached its limit?
    Has the booming PD-1 inhibitor reached its limit? Krebs Qin
    October 18, 2024
    In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
  • Advertising Email to: Julia.zhang@imsinoexpo.com

  • Media Cooperation Email to: Jennifer.Yang@imsinoexpo.com
  • Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

    Note: You can unsubscribe from the alerts at any time.

EZBuy
Livestream & Activity
Conference & Forum
PharmaSources Customer Service